ClinicalTrials.gg
CompletedNCT03844945Updated Oct 19, 2020Results posted

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

A Phase 2 interventional study of Netarsudil Ophthalmic Solution 0.01% and Netarsudil Ophthalmic Solution 0.02% in Open Angle Glaucoma and Ocular Hypertension, sponsored by Aerie Pharmaceuticals. Completed at 25 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-10-19.

Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
215
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.

Enrollment
8th of 17
215 · median 85
Started
2019
the only one that year
Phase 2
6 of 17
none open now
Registered
10th of 17
by date
Lead sponsor
11 of 17
Aerie Pharmaceuticals

Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 8th largest by enrollment, is the only one that started in 2019, is one of 6 in phase 2, and was the 10th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About netarsudil

netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing netarsudil in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan

03

Conditions studied

  • Open Angle Glaucoma
  • Ocular Hypertension

Keywords

  • Glaucoma
  • Ocular Hypertension
  • Open-Angle Glaucoma
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be 20 years of age or older
  2. Diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT) in both eyes. (OAG in one eye and OHT in the fellow eye is acceptable)
  3. BCVA 0.1 or better in decimal unit using Landolt-C chart or its equivalent
  4. Able and willing to give signed and following study instructions

Exclusion criteria

Exclusion Criteria:

  1. ocular diseases
  2. Pseudoexfoliation or pigment dispersion component glaucoma, history of narrow angle closure glaucoma or narrow angles
  3. Previous glaucoma intraocular surgery
  4. Refractive surgery in either eye
  5. Ocular trauma
  6. Ocular infection or inflammation
  7. Known to benzalkonium chloride or of netarsudil ophthalmic solution
  8. Cannot demonstrate proper delivery of the eye drop
  9. Clinically significant abnormalities in screen lab tests
  10. Clinically significant systemic disease
  11. Participation in any study within 30 days of screening
  12. Women of who are pregnant, nursing, planning a pregnancy or not using a medically acceptable form of
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
215 participants (actual)

Study arms

  • Experimental
    Netarsudil Ophthalmic Solution 0.01%

    1 drop daily into each eye in the evening for 28 days

    Drug: Netarsudil Ophthalmic Solution 0.01%

  • Experimental
    Netarsudil Ophthalmic Solution 0.02%

    1 drop daily into each eye in the evening for 28 days

    Drug: Netarsudil Ophthalmic Solution 0.02%

  • Experimental
    Netarsudil Ophthalmic Solution 0.04%

    1 drop daily into each eye in the evening for 28 days

    Drug: Netarsudil Ophthalmic Solution 0.04%

  • Placebo comparator
    Netarsudil Ophthalmic Solution Placebo

    1 drop daily into each eye in the evening for 28 days

    Other: Netarsudil Ophthalmic Solution Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Intraocular Pressure (IOP)

    Mean diurnal IOP within a treatment by Goldman Applanation Tonometry

    Time frame: 29 Days

07

Results

Posted Oct 19, 2020

Participant flow

Participants were recruited at 25 clinical trial sites in Japan.

Participant flow — Overall Study
MilestoneNetarsudil Ophthalmic Solution 0.01%Netarsudil Ophthalmic Solution 0.02%Netarsudil Ophthalmic Solution 0.04%Netarsudil Ophthalmic Solution Placebo
Started55545155
Completed54534654
Not completed1151
Withdrew: Adverse event1140
Withdrew: Withdrawal by subject0010
Withdrew: Lack of efficacy0001

Outcome measures

PrimaryIntraocular Pressure (IOP)

Mean diurnal IOP within a treatment by Goldman Applanation Tonometry

Time frame:
29 Days
Reported as:
Mean · mmHg
Intraocular Pressure (IOP)
mmHgNetarsudil Ophthalmic Solution 0.01%Netarsudil Ophthalmic Solution 0.02%Netarsudil Ophthalmic Solution 0.04%Netarsudil Ophthalmic Solution Placebo
Day 120.5 ± 2.836220.3 ± 2.803920.8 ± 3.203721.1 ± 3.7023
Day 816.2 ± 2.56815.9 ± 2.67315.7 ± 4.01419.8 ± 4.059
Day 1515.9 ± 2.70315.6 ± 2.57315.7 ± 4.19019.3 ± 3.702
Day 2916.3 ± 2.60915.4 ± 2.41116.2 ± 4.49619.3 ± 3.728
Statistical analysis
  • Netarsudil Ophthalmic Solution 0.01% vs Netarsudil Ophthalmic Solution 0.02% vs Netarsudil Ophthalmic Solution 0.04% vs Netarsudil Ophthalmic Solution Placebo · ANCOVA · p = <0.0001

Adverse events

Collected over Ocular/Systemic safety during a 4-week treatment period. Non-serious events are listed at a 0.1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Netarsudil Ophthalmic Solution 0.01%0/55 (0%)0/55 (0%)21/55 (38.2%)
Netarsudil Ophthalmic Solution 0.02%0/54 (0%)0/54 (0%)27/54 (50%)
Netarsudil Ophthalmic Solution 0.04%0/51 (0%)0/51 (0%)36/51 (70.6%)
Netarsudil Ophthalmic Solution Placebo0/55 (0%)0/55 (0%)5/55 (9.1%)
Most frequent other events
Showing 10 of 42
Most frequent other events
EventNetarsudil Ophthalmic Solution 0.01%Netarsudil Ophthalmic Solution 0.02%Netarsudil Ophthalmic Solution 0.04%Netarsudil Ophthalmic Solution Placebo
Conjunctival HyperemiaEye disorders13/5520/5429/511/55
Eye IrritationEye disorders3/555/542/510/55
Conjunctival HemorrhageEye disorders0/553/543/510/55
NasopharyngitisInfections and infestations0/552/543/510/55
Eye painEye disorders0/550/542/510/55
ConjunctivitisInfections and infestations2/550/542/510/55
Eye DischargeEye disorders1/551/541/510/55
Punctate keratitisEye disorders1/550/541/511/55
Vision blurredEye disorders1/551/541/510/55
Visual acuity reducedEye disorders0/551/541/510/55

Baseline characteristics

Randomized Population

Age, Continuous
Age, Continuous(years)Netarsudil Ophthalmic Solution 0.01%Netarsudil Ophthalmic Solution 0.02%Netarsudil Ophthalmic Solution 0.04%Netarsudil Ophthalmic Solution PlaceboTotal
Mean62.7 ± 14.6264.1 ± 12.1662 ± 13.5664.6 ± 12.5863.35 ± 13.23
Sex: Female, Male
Sex: Female, Male(Participants)Netarsudil Ophthalmic Solution 0.01%Netarsudil Ophthalmic Solution 0.02%Netarsudil Ophthalmic Solution 0.04%Netarsudil Ophthalmic Solution PlaceboTotal
Female36292731123
Male1925242492
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Netarsudil Ophthalmic Solution 0.01%Netarsudil Ophthalmic Solution 0.02%Netarsudil Ophthalmic Solution 0.04%Netarsudil Ophthalmic Solution PlaceboTotal
American Indian or Alaska Native00000
Asian55545155215
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
08

Study locations

25 sites
  • Nomura Eye Clinic
    Ichinomiya-shi, Aichi, Japan
  • Shisui ophthalmology clinic
    Shisui, Chiba, Japan
  • Nakamori Eye Clinic
    Kitakyushu-shi, Fukuoka, Japan
  • Southern TOHOKU Eye Clinic
    Koriyama-shi, Fukushima, Japan
  • Kusatsu Eye Clinic
    Hiroshima-shi, Hiroshima, Japan
  • Kanamori Eye Clinic
    Akashi-shi, Hyogo, Japan
  • Sameshima Eye Clinic
    Kagoshima-shi, Kagoshima, Japan
  • Asahigaoka Ophthalmology
    Sendai-shi, Miyagi, Japan
  • Sugao Eye Clinic
    Osaka-shi, Osaka, Japan
  • Yubikai Kawaguchi Aozora Eye Clinic
    Kawaguchi-shi, Saitama-Ken, Japan
  • Hangai Eye Institute
    Saitama-shi, Saitama, Japan
  • Omiya Hamada Eye Clinic West Entrance Branch
    Saitama-shi, Saitama, Japan
  • Omiya Hamada Eye Clinic
    Saitama-shi, Saitama, Japan
  • Shibuya Ophthalmology Clinic
    Saitama-shi, Saitama, Japan
  • Yoshimura Eye & Internal Medical Clinic
    Mishima, Shiizuoka, Japan
  • Medical Corporation Muramatsu Clinic Muramatsu Eye Clinic
    Susono, Shizuoka-ken, Japan
  • Ueda Eye Clinic
    Arakawa-ku, Tokyo, Japan
  • Ochanomizu Inoue Eye Clinic
    Chiyoda-ku, Tokyo, Japan
  • Kiyosawa Eye Clinic
    Koto-Ku, Tokyo, Japan
  • Tamagawa Eye Clinic
    Ota-ku, Tokyo, Japan
  • Seijo Clinic
    Setagaya-Ku, Tokyo, Japan
  • Dogenzaka Kato Eye Clinic
    Shibuya-ku, Tokyo, Japan
  • Wakabadai Eye Clinic
    Shibuya-ku, Tokyo, Japan
  • Hashida Eye Clinic
    Shinagawa-Ku, Tokyo, Japan
  • Watanabe Eye Clinic
    Shinagawa-Ku, Tokyo, Japan
09

References and documents

Publications

  • Araie M, Sugiyama K, Aso K, Kanemoto K, Kothapalli K, Kopczynski C, Senchyna M, Hollander DA. Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension. Adv Ther. 2021 Apr;38(4):1757-1775. doi: 10.1007/s12325-021-01634-9. Epub 2021 Feb 24. PubMed 33629227 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Sep 2019, 6 months.

Results were first posted in Oct 2020, 1 year 1 month after primary completion.

Of 38 industry-sponsored phase 2 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 6 months is below that.

Counting every sponsor, half of 41 studies reached it within 11 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2019
First posted
Feb 19, 2019
StartActual
Mar 19, 2019
Primary completionActual
Sep 19, 2019
CompletionActual
Sep 19, 2019
Results first posted
Oct 19, 2020
Last update
Oct 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03844945
Responsible party
Sponsor
First posted
Feb 19, 2019
Start date
Mar 19, 2019
Primary completion
Sep 19, 2019
Completion
Sep 19, 2019
Results posted
Oct 19, 2020
Last update
Oct 19, 2020

Study contacts

Kenji Aso, M.D., Ph.D.
study director · Aerie Pharmaceuticals Ireland Ltd. (Japan Branch)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion